Case Study

Advancing Immunotherapy In Head And Neck Cancer: The IT-MATTERS Study

Cancer-Cells-Medical-Research-GettyImages-1277229026

Ergomed is proud to have contributed to a significant breakthrough in oncology through the successful delivery of the IT-MATTERS study, one of the largest clinical trials ever conducted globally in Head and Neck Squamous Cell Carcinoma (SCCHN). The study evaluated the use of neoadjuvant Leukocyte Interleukin Injection (LI) immunotherapy in low-risk, locally advanced SCCHN and demonstrated a meaningful improvement in overall survival.

Copyright © 2025 Talor, Tímár, Lavin, Cipriano, Markovic, Ladányi, Karpenko, Bondarenko, Stosic, Sobat, Zhukavets, Imamovic, Chien, Bankowska-Wozniak, Kisely, Jovic, Young and Hao. Pathol. Oncol. Res. 31:1612084. doi: 10.3389/pore.2025.1612084

access the Case Study!

Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.

Subscribe to Clinical Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Clinical Leader

Please tell us more about you so that we can customize our newsletters to your specific interests:

What topics interest you? (Check all that apply.)

Ergomed Clinical Research